Finch Therapeutics Group (FNCH)
(Delayed Data from NSDQ)
$2.30 USD
-0.19 (-7.63%)
Updated May 3, 2024 03:59 PM ET
After-Market: $2.54 +0.24 (10.43%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.30 USD
-0.19 (-7.63%)
Updated May 3, 2024 03:59 PM ET
After-Market: $2.54 +0.24 (10.43%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Finch Therapeutics Group, Inc. (FNCH) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Finch Therapeutics Group, Inc. (FNCH) delivered earnings and revenue surprises of -12.50% and 90.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Ironwood Pharmaceuticals (IRWD) Beats Q3 Earnings Estimates
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of 3.70% and 2.58%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Finch Therapeutics Group, Inc. (FNCH) Upgraded to Buy: Here's Why
by Zacks Equity Research
Finch Therapeutics Group, Inc. (FNCH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.